Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: Meta-analysis of randomized controlled trials

Sasmita Bryan Richard MBBS | Bi Huang MD | Gang Liu MD | Yuan Yang MD | Suxin Luo MD

Elevated resting heart rate in chronic heart failure (HF) patients has been associated with higher mortality and poor prognosis. Ivabradine is a new pure bradycardic agent that has been used to treat angina or heart failure reduced ejection fraction (HFrEF) with sinus heart rate above 70 beats per minute. However, the effect of ivabradine for chronic HF patients on rehospitalization and cardiac function is still inconsistent. Thus, this meta-analysis aimed to elucidate the effect of Ivabradine in chronic HFrEF patients. We systematically searched PubMed, Medline, Clinical Trials.gov, and The Cochrane Central Register of Controlled Trials for randomized controlled trials (RCTs) of ivabradine with search terms Ivabradine (MeSH Terms), chronic heart failure and beta-blocker. The primary endpoints of the study include the impact of Ivabradine on heart rate, left ventricle ejection fraction (LVEF), left ventricular remodeling, exercise capacity, and quality of life (QoL) in patients with chronic HFrEF. Secondary endpoints were safety analysis of Ivabradine including cardiovascular mortality, worsening HF readmission, visual disturbances, and asymptomatic bradycardia. The analysis was done by Review Manager 5.4 Analyzer, to analyze the mean differences (MD) for continuous data and risks ratio (RR) for dichotomous data. A total of six RCTs and one subgroup analysis showed add of Ivabradine to standard HF therapy was associated with greater resting heart rate reduction (MD = −9.57; 95% CI -11.15, −8.00), improved LVEF (MD = 3.89; 95% CI 2.61, 5.17), left ventricular reverse remodeling improvement (MD = −3.73; 95% CI -4.25, −3.21, LVESV; MD = −17.00, 95%CI -29.65, −4.35, LVEDD; MD = −1.43, 95%CI -2.78, −0.08).

Abbreviations: 6MWT, 6 minutes walking test; ACEI, angiotensin converting enzyme inhibitor; AECOPD, acute exacerbation chronic obstructive pulmonary disease; ARB, angiotensin receptor blocker; BEAUTIFUL, effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction; BPM, beats per minute; CHF, chronic heart failure; CI, confidence interval; CQMU, ChongQing Medical University; CVD, cardiovascular death; FDA, Food and Drug Administration; HF, heart failure; HFrEF, heart failure reduced ejection fraction; HR, heart rate; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVESV, left ventricular end-systolic volume; LVSD, left ventricular systolic dysfunction; MD, mean differences; MeSH, medical subject heading; MLWFH, Minnesota living with heart failure; PRISMA, Preferred Reporting Items for Systematic Review and Meta-Analysis; QLMI, quality of life after myocardial infarction; QoL, quality of life; RAAS, renin angiotensin aldosterone system; RCT, randomized controlled trials; RevMan, review manager; RR, risk ratios; SHIFT, effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction.
LVEDV; MD = −14.75, 95%CI -34.36, 4.87), increased exercise capacity (exercise duration; MD = 8.52; 95%CI 0.09, 16.94), and significant reduction on rehospitalization due to worsening HF (RR = 0.76, 95%CI 0.69, 0.84). However, Ivabradine has no significant effect on the quality of life (MD = 0.65; 95%CI -10.52, 11.82), and cardiovascular mortality (RR = 0.92; 95%CI 0.82, 1.03). Moreover, there were some events of visual disturbances and asymptomatic bradycardia observed in the Ivabradine group compared to the placebo group (RR = 4.76; 95%CI 3.03, 7.48; RR = 3.78; 95%CI 2.77, 5.15, respectively). Addition of Ivabradine to standard HF therapy is associated with cardiac function improvement, reduction on worsening HF readmission, greater HR reduction, and better exercise capacity in chronic HFrEF patients, although it cannot reduce cardiovascular mortality or improve the quality of life.

KEYWORDS
chronic heart failure, ejection fraction, ivabradine, LV remodeling, re-hospitalization

1 | BACKGROUND
Elevated heart rate (HR) is an independent risk factor for left ventricular remodeling, poor cardiovascular outcomes, as well as higher all-cause mortality in patients with cardiovascular disease. Framingham study has shown an increment in all-cause mortality by 14% at every 10 beats per minute increase in HR, along with 2-fold increased risk of incident heart failure (HF). The involved mechanisms are possibly related to increased myocardial oxygen demand, accelerate atherosclerosis event, decrease myocardial blood supply, and shortens diastolic time. In patients with HF, previous studies have also show resting HF around 60–70 beats per minute is an important therapeutic goal.

Beta-blocker is essential for the treatment of HF patients due to their efficiency on cardiac remodeling, reduction of hospital readmission, and cardiovascular death. Although beta-blocker is regarded as the first-line agent for HF patients, several contraindications, complications, and side effects, such as hypotension, worsening cardiac function, asthma, acute exacerbation of chronic obstructive pulmonary disease may limit its use in clinical practice.

Ivabradine is the new promising pure bradycardic agent without affecting cardiac conductivity. Ivabradine is selectively acted to lower the HR through specific inhibition of the I_{f} channel in the sinus node, thus resulting in a reduction of HR by prolonging diastolic depolarization of a pacemaker action potential. Ivabradine was officially approved by US FDA for the treatment of HF in 2015 with indications of heart failure reduced ejection fraction (HFrEF) and sinus rhythm ≥70 beats per minute on a maximal dosage of beta-blocker or when beta-blocker is contraindicated. To date, there are only two large studies conducted the use of Ivabradine in HF patients including BEAUTIFUL study and SHIFT study; however, both studies had different inclusion criteria and the findings were inconsistent. Several other studies have also reached inconsistent conclusions. Accordingly, this meta-analysis was designed to evaluate the safety and efficiency of Ivabradine added to the standard HF treatment in patients with chronic HFrEF.

2 | METHODS
This study was conducted per standard article publication in Medical Journals, as this article has been made in coherence with Preferred Reporting Items for Meta-Analysis PRISMA Checklist.

2.1 | Search strategy
We systematically searched PubMed, Medline, Clinical Trials.gov, and The Cochrane Central Register of Controlled Trials for RCTs with search terms Ivabradine (MeSH terms), chronic heart failure and beta-blocker without any specific time restriction (Figure 1).

2.2 | Inclusion/exclusion criteria
RCTs with the following inclusion criteria are included: RCT on Ivabradine and published in English; chronic HFrEF; Effect and safety of added Ivabradine (2.5–7.5 mg bid) compared to control group with standard optimal medical treatment, including beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics, and aldosterone antagonist; Echocardiographic assessment; Exercise tolerance and quality of life (supplement Table 1).

The exclusion criteria were as following: (1) Non-human studies; (2) Articles in a language other than English; (3) No follow up data; (4) Other types of HF; (5) No comparison between intervention and control groups (Table 1).
2.3 | Outcomes

2.3.1 | Therapeutic effect

The main outcomes were the effect of added Ivabradine treatment on chronic HF patient's HR, LVEF, left ventricular remodeling, exercise capacity, and QoL. Evaluation index of reverse remodeling were left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular end-diastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV). Assessment for exercise capacity was measured with exercise duration, meanwhile, Minnesota Living with Heart Failure (MLWHF) questionnaire were used to detect an improvement in the QoL of HF patients. (supplement Tables 2 and 3).

2.3.2 | Safety

Adverse events include cardiovascular mortality, rehospitalization for worsening HF, asymptomatic bradycardia, and visual disturbances were recorded in Ivabradine and placebo groups.

2.4 | Data analysis

Data analysis was done by using RevMan 5.4, dichotomous data are reported by using Mantel–Haenszel statistical method, fixed/random effects analysis model, risk ratio effect measure with 95% CIs, while Continuous variables are evaluated using mean differences (MD) with 95% CIs. Effect model was used in data analysis depends on the degree of heterogeneity and P-value, a fixed-effect model was used if $I^2 < 50\%$ and low $P$-value $<.10.$ If heterogeneity was detected, subgroup analyses to explore the source of heterogeneity will be conducted. Meanwhile, a sensitivity analysis to evaluate robustness of the outcomes was done by removing the study with high risk or unclear risk of selection bias.

2.5 | Assessment risk of bias and quality of studies

The Cochrane risk of bias domains were used to analyze the bias ratings of each study. The selection of domains includes random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. Ratings of bias are divided into low risk, unclear risk, and high risk. Quality of evidence extracted by two independent investigators (Richard Bryan and Bi Huang), where the disagreement about inclusion data will be settled by a third investigator (Gang Liu) through a discussion and consensus.

3 | RESULTS

In total, six RCTs and one subgroup analysis with 7074 participants (3523 in the placebo group, 3551 in the Ivabradine group) were enrolled in this meta-analysis. The main outcomes of this study were the effect of Ivabradine therapeutic on HR, LVEF, exercise capacity, QoL, and left ventricular remodeling. The high heterogeneity presented might be attributed to a distinct measurement index, insufficient number of studies on preferred outcomes, and different baseline characteristics of represented studies, such as sample size, age, gender, and follow-up time.

3.1 | Effect of ivabradine on main outcomes

Six RCTs included in our study showed that Ivabradine added to the standard HF treatment was associated with a better optimization for resting HR reduction in chronic HFrEF patients (MD = −9.57; 95% CI −11.15, −8.00) compared to the placebo group. Sensitivity analysis with removal of high risk or unclear risk selection bias study showed consistent findings on the effect of Ivabradine for further HR reduction (MD = −10.37; 95%CI −12.10, −8.64) (Figure 2).

Five RCTs (420 in Placebo, 472 in Ivabradine) demonstrated treatment with added Ivabradine significantly increased LVEF in the chronic HFrEF patients (MD = 3.89; 95% CI 2.61, 5.17). Sensitivity analysis maintained the effect of LVEF improvement (MD = 4.07; 95%CI 2.72, 5.42) (Figure 3). A sensitivity analysis maintained the effect of LVEF improvement (MD = 4.07; 95% CI 2.72, 5.42).

Three echocardiographic studies of chronic HFrEF (252 in Placebo, 264 in Ivabradine) were enrolled to observe the possibility of Ivabradine for left ventricular remodeling. Analysis was done by dividing parameter index into four groups including LVEDD, LVESD, LVEDV, and LVESV. Based on these four
| Study or Sub-study | Method | Participants | Intervention | Outcome | Duration |
|-------------------|--------|---------------|--------------|---------|----------|
| Tsutsui H et al 2019\textsuperscript{22} | Randomized Controlled Trial | 254 Japanese patients with age $\geq$ 20 years old, stable symptomatic chronic HF or NYHA class II-IV, LVEF $\leq$ 35%, resting HR $\geq$ 75 beats/min in sinus rhythm, received optimal, stable treatment according to Japanese Guideline for Treatment of Chronic Heart Failure and had a history of hospital for worsening HF within the preceding 52 weeks (127 assigned to Ivabradine group, 127 assigned to Placebo) | Ivabradine 5–7.5 mg bid | The primary endpoint was the composite of cardiovascular death or hospital admission for worsening HF. | 582 days |
| Sarullo et al 2010\textsuperscript{24} | Randomized Controlled Trial | 60 patients with symptoms of heart failure, LVEF $\leq$ 40%, NYHA classes II to III, sinus rhythm with heart rate at rest $>70$ beats per minute (bpm), on optimal medical treatment of HF. (30 assigned to Ivabradine group, 30 assigned to Placebo group) | Ivabradine 5 mg bid | Evaluate use of Ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in pts with ischemic CHF | 3 months |
| Mansour et al 2011\textsuperscript{21} | Randomized Controlled Trial | 53 Idiopathic DCM patients with NYHA class III or IV, LVEF $<40\%$, sinus rhythm, resting heart rate $\geq 70$ beats/min, on beta-blocker and ACEI treatment. (30 assigned to Ivabradine group, 23 assigned to Placebo group) | Ivabradine 5–7.5 mg bid | The effect of Ivabradine on symptoms, quality of life, effort tolerance, and echocardiographic parameters in patients with idiopathic DCM with NYHA class III or IV. | 3 months |
| Tsutsui H et al 2016\textsuperscript{23} | Randomized controlled trial | 126 Japanese patients with age $\geq$ 20 years old, resting HR $\geq$ 75 beats/min in sinus rhythm, stable symptomatic chronic HF of NYHA class II or higher, LVEF $\leq$ 35%, and under optimal, stable treatment according to Japanese Guideline for Treatment of Chronic Heart Failure (JCS 2010) (84 assigned to Ivabradine group, 42 assigned to Placebo) | Ivabradine 2.5–5 mg bid | Reduction in resting heart rate after 6 weeks treatment. | 6 weeks |
| SHIFT 2010\textsuperscript{20} | Randomized controlled trial | 6558 patients with symptomatic heart failure and LVEF $\leq$ 35%, heart rate of 70 bpm or higher (3268 assigned to Ivabradine; 3290 assigned to Placebo group) | Ivabradine 2.5–7.5 mg bid | Cardiovascular death or Hospital readmission for worsening heart failure. | 27.8 months |
| Tardif JC et al 2011 (SHIFT sub-study)\textsuperscript{26} | Randomized controlled Trial | 611 Eligible patients in sinus rhythm, resting heart rate $\geq 70$ beats/min (bpm), clinically stable for $\geq 4$ weeks, worsening HF within the previous 12 months, and on optimal background therapy for HF including a beta-blocker. (304 assigned to Ivabradine, 307 assigned to Placebo group) | Ivabradine 2.5–7.5 mg bid | Evaluate the effect of Ivabradine on left ventricular (LV) remodeling in heart failure (HF) | 8 months |
| Volterrani M et al 2011\textsuperscript{27} | Randomized controlled trial | 80 Eligible patients aged 18 to 90 years, had been diagnosed with HF at least 12 months prior, NYHA Class II-III, clinically stable for 3 weeks prior to selection or discharged in stable conditions. Patients were receiving optimal background therapy for HF (beta-blocker, ACEI, ARB, diuretics, aldosterone antagonist) for 3 months. (42 assigned to Ivabradine, 38 assigned to Placebo group) | Ivabradine 2.5–7.5 mg bid | Effect of Ivabradine on the distance covered in 6 minutes walking test (6MWT) and maximal oxygen consumption (MVO$_2$) on cardiopulmonary exercise test. | 3 months |
parameters, our study showed added Ivabradine on the standard HF therapy distinctly improved echocardiographic parameters, with only LVEDV not achieving statistical significance (LVESD; MD = −3.73; 95% CI -4.25, -3.21, LVESV; MD = −17.00, 95%CI -29.65, -4.35, LVEDD; MD = −1.43, 95%CI -2.78, -0.08, LVEDV; MD = −14.75, 95%CI -34.36, 4.87) (supplement Figure 1). A sensitivity analysis was performed on LVEDV and LVESV, with LVESV maintained the positive outcome, while LVEDV displayed no significant differences (MD = −5.77; 95%CI -11.94, 0.39; MD = −11.48; 95%CI -17.10, -5.86, respectively).

Exercise capacity between optimal HF treatment compared to added Ivabradine treatment was measured by total exercise duration.21,24 It revealed added Ivabradine had better exercise tolerance than placebo group (MD = 8.52; 95% CI 0.09, 16.94) (supplement Figure 2).

Two studies (53 in Placebo, 60 in Ivabradine) were enrolled to observe the improvement of QoL in chronic HFrEF patients. It indicated that added Ivabradine treatment had no significant effect on MLWHF score (MD = 0.65; 95%CI -10.52, 11.82) (supplement Figure 3).

### 3.2 Adverse events

The therapeutic safety evaluation index of Ivabradine was analyzed by using risk ratio, and fixed/random effect model. Included side effects were cardiovascular death, rehospitalization for worsening HF, visual disturbances, and asymptomatic bradycardia. Despite that multiple large studies showed inconsistency results on HF rehospitalization,19,20,28 our meta-analysis showed significant reduction for worsening HF rehospitalization with Ivabradine treatment (RR = 0.76; 95%CI 0.69, 0.84), no significant differences for cardiovascular mortality (RR = 0.92; 95%CI 0.82, 1.03). Visual disturbances and asymptomatic bradycardia events were significantly increased in Ivabradine group (RR = 4.76; 95%CI 3.03, 7.48; RR = 3.78; 95%CI 2.77, 5.15) (Figure 4).
3.3 | Risk of bias and quality assessment

Based on the Cochrane Collaboration for risk of bias assessment criteria, enrolled studies presented various risk of bias. Moreover, the assessment of other possible bias is uncertain due to insufficient information from respective studies (supplement Figure 4).

3.4 | Investigation of heterogeneity

High heterogeneity investigation in the resting HR was stratified into two subgroups based on age and follow-up duration. First, included studies were grouped based on the age < 60 years old and ≥ 60 years old and revealed that the results were consistent in the two different age groups (MD = -11.40; 95%CI -13.08, -9.72; MD = -8.46; 95%CI -10.24, -6.68, respectively). However, substantial heterogeneity presented in the subgroup of ≥60 years old ($I^2 = 65\%$), but not in the <60 years old group ($I^2 = 0\%$), thus indicating aging was one of the reasons for the high heterogeneity.

Second, subgroup analysis was performed based on the duration of Ivabradine treatment for HR reduction with distinction <6 months and ≥ 6 months. In the <6 months subgroup, four RCTs demonstrated high heterogeneity (MD = -9.84; 95%CI -13.11, -6.58; $I^2 = 79\%$), nevertheless in ≥6 months group 2 RCTs showed no heterogeneity (MD = -9.03; 95%CI -9.49, -8.57; $I^2 = 0\%$).

In the present study, high heterogeneity also existed in the other outcomes, such as in the left ventricular remodeling indexes, exercise capacity, and QoL. As for the LV remodeling parameters, after conducting a sensitivity analysis, low heterogeneity was displayed on LVEDV and LVESV. Meanwhile, owing to an insufficient number of studies, subgroup analyses for exercise capacity and QoL was unable to be conducted.

4 | DISCUSSION

The present meta-analysis demonstrated apart from several adverse events mentioned, added Ivabradine treatment was not only safe, but also effective for HR reduction, improvement of cardiac function, and better exercise tolerance in patients with chronic HFrEF. To the best of our knowledge, this meta-analysis is among the few meta-analyses to discuss the effect of Ivabradine in chronic HFrEF patients.

In terms of the efficiency of Ivabradine, the present meta-analysis complies with SHIFT study and Pei et al’s study in which Ivabradine could reduce the risk of worsening HF readmission (HR = 0.74; 95%CI 0.66, 0.83, RR = 0.91; 95%CI 0.85, 0.97, respectively). However, the finding was not confirmed by other three meta-
analyses in which Koroma, et al, Benstoem C, et al, and Anantha, et al meta-analyses demonstrated no significant reduction in worsening HF rehospitalization. The inconsistent conclusion was possibly due to the different inclusion criteria in a respective study such as in Anantha, et al meta-analysis which included one acute HF study and one stable angina study in addition to HF studies, while our meta-analysis only included chronic HFrEF studies. Moreover, although several meta-analyses including ours reached similar conclusions such as the improvement of LVEF after addition of Ivabradine to standard therapy, however, our study also had some distinctive features compared with these meta-analyses. First, the most important superiority is that the participants in our meta-analysis were pure patients with chronic HFrEF. Second, we reconfirmed the neutral effect of Ivabradine on cardiovascular mortality in chronic HFrEF patients, although it could improve LVEF. Moreover, we systematically evaluated the safety and efficiency with clinical events, echocardiographic parameters, exercise tolerance and QoL scores while other meta-analyses mainly focused on some specific issues such as HR changes, cardiac remodeling, diastolic dysfunction or the safety of Ivabradine.

Ivabradine lead to improvement in HR and LVEF was mainly attributed to the fact that the combination with beta-blocker produces a significant reduction in the resting HR. Tsutsui, et al demonstrated that high-dose (7.5 mg bid) of Ivabradine had a greater reduction in the HR change compared to low-dose (2.5 mg bid) of Ivabradine (84.0 ± 7.5 to 67.1 ± 8.0, 81.2 ± 7.0 to 66.0 ± 9.0, respectively). In fact, due to the HR reduction mechanism, Ivabradine at first was recognized as an anti-anginal agent and several studies also enrolled patients with stable coronary artery disease as the main inclusion criteria such as the BEAUTIFUL and SIGNIFY studies. However, these studies demonstrated no significant improvement in terms of all-cause death, readmission to hospital for worsening HF, and cardiovascular death. This finding is supported by Maagaard M, et al's meta-analysis. Our present meta-analysis had superiority with only RCTs with chronic HFrEF patients and could reach reliable conclusions.

Association between dosage of Ivabradine and LVEF improvement was also found in some studies. Tsutsui, et al demonstrated higher dosage of Ivabradine was positively associated with better improvement in LVEF (5 mg bid, 28.6 ± 4.8 to 35.0 ± 10.4; 2.5 mg bid, 28.4 ± 5.6 to 33.8 ± 8.7). This finding is consistent with Raja, et al's study in which HR ≤ 70 beats per minute had higher LVEF compared with that of HR > 70 beats per minute (30.4 ± 3.8%, 27.6 ± 3.6, respectively). These studies indicated that optimal control of HR to less than 70 beats per minute with Ivabradine was more beneficial to the LVEF improvement.

Moreover, the improvement of exercise capacity is beneficial from the combination of beta-blocker and Ivabradine which increase the beta-blocker non-selective effects on the alpha-adrenergic receptor, thus affect muscle-skeletal dilatation during exercise. Furthermore, Ivabradine has been shown to preserve exercise-induced vasodilation, increase muscular blood flow during exercise, and improvement on peripheral blood flow. Volterrani M, et al assessed the effect of Ivabradine on chronic HF patient’s exercise tolerance by using 6 minutes walking test, in which the Ivabradine group demonstrated greater improvement than placebo group (Ivabradine: 358.2 ± 107.6 to 453.1 ± 87.4; Placebo: 379.0 ± 96.3 to 435.7 ± 121.3). Our meta-analysis is also in compliance with Koroma, et al finding which Ivabradine therapy increased exercise tolerance (6MWT: SMD = −1.01; 95%CI -0.59, −0.06).

Most studies inferred the observed effect of Ivabradine on QoL improvement was likely to be related to exercise capacity improvement, although our present meta-analysis showed no significant difference in QoL improvement between the two groups. However, we found two studies displayed a positive association between Ivabradine with chronic HF patients’ QoL improvement. Ekman I, et al conducted a SHIFT trial sub-study on the association of Ivabradine with QoL improvement by using the Kansas City Cardiomyopathy Questionnaire (KCCQ) and they found that added Ivabradine treatment demonstrated better KCCQ overall summary score (Placebo 65.3 ± 19.8 to 69.6 ± 16.7; Ivabradine 65.2 ± 20 to 71.9 ± 17.3, p = .001). Moreover, Volterrani M, et al observed quality of life improvement by using MacNew QLMI (quality of life after myocardial infarction) questionnaire in patients with HF complicating myocardial infarction, and they found Ivabradine group (4.7 ± 0.8–6.1 ± 0.6) showed higher QoL improvement than placebo group (4.6 ± 0.8–4.1 ± 0.6).

Ivabradine was thought to have no relation with renin angiotensin aldosterone (RAA) system and the sympathetic nervous system, therefore, theoretically, Ivabradine does not affect cardiac reverse remodeling. However, our meta-analysis included two RCTs and one subgroup analysis favors adding Ivabradine for reverse remodeling in chronic HFrEF patients. This finding was in accordance with Chan H, et al’s study, which demonstrated Ivabradine had a positive association with reverse cardiac remodeling (LVESVI; MD = −7.30; 95%CI -12.94, −1.66; LVEDVI; MD = −7.27; 95%CI -14.04, −0.50). Several studies hypothesized the potential mechanisms associated with Ivabradine improving cardiac remodeling were the modification in cardiac myocyte function, optimization of energy consumption, improvement of endothelial function, a reversal in electrophysiological changes, to the extent of reduction of RAAS stimulation and sympathetic drive etc.

However, due to insufficient large RCTs, we still cannot conclude whether Ivabradine can absolutely improve left ventricular remodeling or not, also to what extent Ivabradine can improve the outcome, therefore more large studies are still needed to clarify the role that Ivabradine played in cardiac remodeling.

5 | LIMITATIONS

There are several unavoidable limitations in this study. First, although we included six RCTs and one subgroup analysis associated with Ivabradine efficiency and safety in patients with chronic HFrEF, however, the high heterogeneity and the numbers of patients included to each study contributed to the statistical analysis and conclusion.
Second, different parameter indices associated with LV remodeling, exercise capacity, and quality of life were used in different studies, thus limiting the analysis with the same parameters and also the final conclusion. Third, echocardiographic indexes as ventricular remodeling indicators are easily affected by afterload and preload, thus careful and repeated measurement of cardiac echocardiography is necessary. Fourth, most of the included studies only provided average doses of Ivabradine and therefore we could not get the dose-effect relationship. Therefore, more large-scale studies are still needed to elucidate the association of Ivabradine with the outcome in patients with chronic HFrEF.

6 CONCLUSIONS

Addition of Ivabradine to standard HF therapy is associated with cardiac function improvement, reduction on worsening HF readmission, greater HR reduction, and better exercise capacity in chronic HFrEF patients, although it cannot reduce cardiovascular mortality or improve the quality of life.

CONFLICT OF INTEREST

The authors declare no competing interests.

DATA AVAILABILITY STATEMENT

The data that supports the findings of this study are available in the supplementary material of this article.

ORCID

Sasmita Bryan Richard https://orcid.org/0000-0003-3286-8915

REFERENCES

1. Kannel WB, Kannel C, Paffenbarger RS Jr, et al. Heart rate and cardiovascular mortality: the Framingham study. Am Heart J. 1987;113(6):1489-1494. https://doi.org/10.1016/0002-8703(87)90666-1.
2. Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50(9):823-830. https://doi.org/10.1016/j.jacc.2007.04.079.
3. Kannel WB. Risk stratification in hypertension: new insights from the Framingham study. Am J Hypertens. 2000;13(1 Pt 2):35-105. https://doi.org/10.1016/s0895-7061(99)00252-6.
4. Komajda M, Isnard R, Cohen-Solal A, et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail. 2017;19(11):1495-503. https://doi.org/10.1002/ejhf.876. [published Online First: 2017/05/04]
5. Palatini P, Julius S. Association of tachycardia with morbidity and mortality: physiological considerations. J Hum Hypertens. 1997;11(suppl 1):S19-S27.
6. Cook S, Togni M, Schaub MC, et al. High heart rate: a cardiovascular risk factor? Eur Heart J. 2006;27(20):2387-2393. https://doi.org/10.1093/eurheartj/ehl259.
7. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372(9641):817-821. https://doi.org/10.1016/S0140-6736(08)61171-X.
8. Reil JC, Bohm M. The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol. 2007;96(9):585-592. https://doi.org/10.1007/s00392-007-0537-5.
9. Custodis F, Schirmer SH, Baumhakel M, et al. Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol. 2010;56(24):1973-1983. https://doi.org/10.1016/j.jacc.2010.09.014.
10. Ho JE, Larson MG, Gorgbani A, et al. Long-term cardiovascular risks associated with an elevated heart rate: the Framingham heart study. J Am Heart Assoc. 2014;3(3):e000668. https://doi.org/10.1161/JAHA.113.000668.
11. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007.
12. A randomized trial of beta-blockade in heart failure. The cardiac insufficiency Bisoprolol study (CIBIS). CIBIS investigators and committees. Circulation. 1994;90(4):1765-1773. https://doi.org/10.1161/01.cir.90.4.1765.
13. The cardiac insufficiency Bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13.
14. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in dilated cardiomyopathy (MDC) study trial group. Lancet. 1993;342(8885):1441-1446. https://doi.org/10.1016/0140-6736(93)92930-r.
15. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651-1658. https://doi.org/10.1056/NEJM200105313442201.
16. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group. N Engl J Med. 1996;334(21):1349-1355. https://doi.org/10.1056/NEJM199605233210101.
17. DiFrancesco D, Camm JA. Heart rate lowering by specific and selective (I) current inhibition with ivabradine: a new therapeutic perspective in cardiac disease. Drugs. 2004;64(16):1757-1765. https://doi.org/10.2165/00003495-200464160-00003.
18. Task Force Members, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003. https://doi.org/10.1093/eurheartj/eht296.
19. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807-816. https://doi.org/10.1016/S0140-6736(08)61170-7.
20. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875-885. https://doi.org/10.1016/S0140-6736(10)61198-1.
21. Mansour S, Yousef A, Rayan M, Ayman Saleh M. Efficacy of ivabradine in idiopathic dilated cardiomyopathy patients with chronic heart failure. Egyptian Heart J. 2011;63:79-85. https://doi.org/10.1016/j.ejhj.2011.09.001.
22. Tsutsui H, Momomura SI, Yamashina A, et al. Efficacy and safety of Ivabradine in Japanese patients with chronic heart failure- J-SHIFT study. Circ J. 2019;83(10):2049-2060. https://doi.org/10.1253/circj.CJ-19-0227.
23. Tsutsui H, Momomura S, Yamashina A, et al. Heart rate control with if inhibitor, Ivabradine, in Japanese patients with chronic heart failure- a randomized, double-blind, placebo-controlled phase II study. Circ J. 2016;80(3):668-676. https://doi.org/10.1253/circj.CJ-15-1112.
24. Sarullo FM, Fazio G, Puccio D, et al. Impact of “off-label” use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohumoral modulation in patients with ischemic
chronic heart failure. J Cardiovasc Pharmacol Ther. 2010;15(4):349-355. https://doi.org/10.1177/1074248410370326.

25. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339:b2700. doi: https://doi.org/10.1136/bmj.b2700

26. Tardif JC, O’Meara E, Komajda M, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32(20):2507-2515. https://doi.org/10.1093/eurheartj/ehr311.

27. Volterrani M, Cice G, Caminiti G, et al. Effect of carvedilol, Ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial). Int J Cardiol. 2011;151(2):218-224. https://doi.org/10.1016/j.ijcard.2011.06.098.

28. Fox K, Ford I, Ferrari R. Ivabradine in stable coronary artery disease. N Engl J Med. 2014;371(25):2435. https://doi.org/10.1056/NEJMc1413158.

29. Pei H, Miao W, Xie WZ, et al. Ivabradine improves cardiac function and increases exercise capacity in patients with chronic heart failure. Int Heart J. 2019;60(4):899-909. https://doi.org/10.1536/ihj.18-559.

30. Koroma TR, Samura SK, Cheng Y, Tang M. Effect of Ivabradine on left ventricular diastolic function, exercise tolerance and quality of life in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. Cardiol Res. 2020;11(1):40-49. https://doi.org/10.14740/cr958.

31. Benstoem C, Kalvelage C, Breuer T, et al. Ivabradine as adjuvant treatment for chronic heart failure. Cochrane Database Syst Rev. 2020;11:CD013004. https://doi.org/10.1002/14651858.CD013004.pub2.

32. Anantha Narayanan M, Reddy YN, Baskaran J, Deshmukh A, Benditt DG, Raveendran G. Ivabradine in the treatment of systolic heart failure - a systematic review and meta-analysis. World J Cardiol. 2017;9(2):182-190. https://doi.org/10.4330/wjc.v9.i2.182.

33. Hidalgo FJ, Anguita M, Castillo JC, et al. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): a randomised study. Int J Cardiol. 2016;217:7-11. https://doi.org/10.1016/j.ijcard.2016.04.136.

34. Amosova E, Andrejev E, Zaderey I, Rudenko U, Ceconi C, Ferrari R. Efficacy of ivabradine in combination with Beta-blocker versus up titration of Beta-blocker in patients with stable angina. Cardiovasc Drugs Ther. 2011;25(6):531-537. https://doi.org/10.1007/s10557-011-6327-3.

35. Wan H, Huang T, Zhang H, et al. Effects of Ivabradine on cardiac remodeling in patients with stable symptomatic heart failure: a systematic review and meta-analysis. Clin Ther. 2020. 42(12):2289–2297. https://doi.org/10.1016/j.clinthera.2020.10.005.

36. Maagaard M, Nielsen EE, Sethi NJ, et al. Effects of adding Ivabradine to usual care in patients with angina pectoris: a systematic review of randomised clinical trials with meta-analysis and Trial sequential analysis. Open Heart. 2020;7(2):e001288.

37. Raja DC, Kapoor A, Sinha A, et al. Heart rate manipulation in dilated cardiomyopathy: assessing the role of Ivabradine. Indian Heart J. 2018;70(2):246-251. https://doi.org/10.1016/j.ihj.2017.08.009.

38. Simon L, Ghaleb B, Puybasset L, et al. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275(2):659-666.

39. Ekman I, Chassany O, Komajda M, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011;32(19):2395-2404. https://doi.org/10.1093/eurheartj/ehr343.

40. Verschueren M, Favre J, Mulder P, et al. Protection of endothelial function by long term heart rate reduction induced by ivabradine in a rat model of chronic heart failure. Fundam Clin Pharmacol. 2007;21:22-22.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Bryan Richard S, Huang B, Liu G, Yang Y, Luo S. Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: Meta-analysis of randomized controlled trials. Clin Cardiol. 2021;44:463-471. https://doi.org/10.1002/clc.23581